Anzeige
Meldung des Tages: Breaking News: Diese Kupfer-Aktie zündet in den USA den nächsten Deep-Drill-Schritt

Edgewise Therapeutics News

Aktie
WKN:  A2QRZ8 ISIN:  US28036F1057 US-Symbol:  EWTX Branche:  Biotechnologie Land:  USA
29,04 $
-1,03 $
-3,43%
25,097 € 20.03.26
Depot/Watchlist
Marktkapitalisierung *
2,10 Mrd. €
Streubesitz
-
KGV
-15,36
Index-Zuordnung
-

Edgewise Therapeutics News

16.08.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX PR Newswire
11.08.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX PR Newswire
07.08.25 - PR Newswire
Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights PR Newswire
06.08.25 - PR Newswire
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire
06.08.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX PR Newswire
31.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX PR Newswire
27.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX PR Newswire
22.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX PR Newswire
17.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX PR Newswire
12.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX PR Newswire
07.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX PR Newswire
02.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX PR Newswire
27.06.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX PR Newswire
26.06.25 - PR Newswire
Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies
Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies PR Newswire
03.06.25 - PR Newswire
Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference
Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference PR Newswire
14.05.25 - PR Newswire
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025 PR Newswire
08.05.25 - PR Newswire
Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights PR Newswire
02.04.25 - PR Newswire
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock PR Newswire
02.04.25 - PR Newswire
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-​HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) PR Newswire
26.03.25 - PR Newswire
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-​HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on ...

Newssuche

Videos

newspaper
19.03.26
COUNTER HUNTER Strategie Einführung
Live-​Seminar am 29.3. ab 14 Uhr! Wie immer wird die Schulung auch aufgezeichnet und allen ... Mehr »